Table of Contents

1 Study Coverage

• 1.1 Neuroleptics Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Neuroleptics Market Size Growth Rate by Product
  • 1.4.2 First Generation
  • 1.4.3 Second Generation
  • 1.4.4 Third Generation
• 1.5 Market by End User
  • 1.5.1 Global Neuroleptics Market Size Growth Rate by End User
  • 1.5.2 Schizophrenia
  • 1.5.3 Bipolar Disorder
  • 1.5.4 Unipolar Depression
  • 1.5.5 Dementia
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Neuroleptics Market Size
  • 2.1.1 Global Neuroleptics Revenue 2014-2025
  • 2.1.2 Global Neuroleptics Sales 2014-2025
• 2.2 Neuroleptics Growth Rate by Regions
  • 2.2.1 Global Neuroleptics Sales by Regions
  • 2.2.2 Global Neuroleptics Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Neuroleptics Sales by Manufacturers
  • 3.1.1 Neuroleptics Sales by Manufacturers
  • 3.1.2 Neuroleptics Sales Market Share by Manufacturers
  • 3.1.3 Global Neuroleptics Market Concentration Ratio (CR5 and HHI)
• 3.2 Neuroleptics Revenue by Manufacturers
  • 3.2.1 Neuroleptics Revenue by Manufacturers (2014-2019)
  • 3.2.2 Neuroleptics Revenue Share by Manufacturers (2014-2019)
• 3.3 Neuroleptics Price by Manufacturers
• 3.4 Neuroleptics Manufacturing Base Distribution, Product Types
  • 3.4.1 Neuroleptics Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Neuroleptics Product Type
  • 3.4.3 Date of International Manufacturers Enter into Neuroleptics Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Neuroleptics Sales by Product
• 4.2 Global Neuroleptics Revenue by Product
• 4.3 Neuroleptics Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Neuroleptics Breakdown Data by End User

6 North America

• 6.1 North America Neuroleptics by Countries
  • 6.1.1 North America Neuroleptics Sales by Countries
  • 6.1.2 North America Neuroleptics Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Neuroleptics by Product
• 6.3 North America Neuroleptics by End User

7 Europe

• 7.1 Europe Neuroleptics by Countries
  • 7.1.1 Europe Neuroleptics Sales by Countries
  • 7.1.2 Europe Neuroleptics Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Neuroleptics by Product
• 7.3 Europe Neuroleptics by End User

8 Asia Pacific

• 8.1 Asia Pacific Neuroleptics by Countries
  • 8.1.1 Asia Pacific Neuroleptics Sales by Countries
  • 8.1.2 Asia Pacific Neuroleptics Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Neuroleptics by Product
• 8.3 Asia Pacific Neuroleptics by End User

9 Central & South America

• 9.1 Central & South America Neuroleptics by Countries
  • 9.1.1 Central & South America Neuroleptics Sales by Countries
  • 9.1.2 Central & South America Neuroleptics Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Neuroleptics by Product
• 9.3 Central & South America Neuroleptics by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Neuroleptics by Countries
  • 10.1.1 Middle East and Africa Neuroleptics Sales by Countries
  • 10.1.2 Middle East and Africa Neuroleptics Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Neuroleptics by Product
• 10.3 Middle East and Africa Neuroleptics by End User

11 Company Profiles

• 11.1 Johnson & Johnson
  • 11.1.1 Johnson & Johnson Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Johnson & Johnson Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Johnson & Johnson Neuroleptics Products Offered
  • 11.1.5 Johnson & Johnson Recent Development
• 11.2 Pfizer
  • 11.2.1 Pfizer Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Pfizer Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Pfizer Neuroleptics Products Offered
  • 11.2.5 Pfizer Recent Development
• 11.3 Eli Lilly
  • 11.3.1 Eli Lilly Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Eli Lilly Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Eli Lilly Neuroleptics Products Offered
  • 11.3.5 Eli Lilly Recent Development
• 11.4 Bristol-Myers Squibb
  • 11.4.1 Bristol-Myers Squibb Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Bristol-Myers Squibb Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Bristol-Myers Squibb Neuroleptics Products Offered
  • 11.4.5 Bristol-Myers Squibb Recent Development
• 11.5 AstraZeneca
  • 11.5.1 AstraZeneca Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 AstraZeneca Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 AstraZeneca Neuroleptics Products Offered
  • 11.5.5 AstraZeneca Recent Development
• 11.6 GSK
  • 11.6.1 GSK Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 GSK Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 GSK Neuroleptics Products Offered
  • 11.6.5 GSK Recent Development
• 11.7 Allergan
  • 11.7.1 Allergan Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Allergan Neuroleptics Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Allergan Neuroleptics Products Offered
  • 11.7.5 Allergan Recent Development

12 Future Forecast

• 12.1 Neuroleptics Market Forecast by Regions
  • 12.1.1 Global Neuroleptics Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Neuroleptics Revenue Forecast by Regions 2019-2025
• 12.2 Neuroleptics Market Forecast by Product
  • 12.2.1 Global Neuroleptics Sales Forecast by Product 2019-2025
  • 12.2.2 Global Neuroleptics Revenue Forecast by Product 2019-2025
• 12.3 Neuroleptics Market Forecast by End User
• 12.4 North America Neuroleptics Forecast
• 12.5 Europe Neuroleptics Forecast
• 12.6 Asia Pacific Neuroleptics Forecast
• 12.7 Central & South America Neuroleptics Forecast
• 12.8 Middle East and Africa Neuroleptics Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Neuroleptics Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Neuroleptics are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. They are increasingly being used in the management of non-psychotic disorders. Antipsychotics are usually effective in relieving symptoms of psychosis in the short term.
The global Neuroleptics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neuroleptics market based on company, product type, end user and key regions.

This report studies the global market size of Neuroleptics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroleptics in these regions.
This research report categorizes the global Neuroleptics market by top players/brands, region, type and end user. This report also studies the global Neuroleptics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Johnson & Johnson
Pfizer
Eli Lilly
Bristol-Myers Squibb
AstraZeneca
GSK
Allergan

Market size by Product
First Generation
Second Generation
Third Generation
Market size by End User
Schizophrenia
Bipolar Disorder
Unipolar Depression
Dementia
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Neuroleptics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neuroleptics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neuroleptics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neuroleptics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Neuroleptics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroleptics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.